User login
Calcitonin gene–related peptide (CGRP) monoclonal antibodies for migraine prevention will take center stage at the upcoming annual meeting of the American Academy of Neurology in Boston in a variety of talks aimed at describing the latest clinical trial findings.
Amaal J. Starling, MD, of the Mayo Clinic, Phoenix, Ariz., will lead off on the topic in the Contemporary Clinical Issues Plenary Session on April 24 by discussing in her presentation, “The Era of Targeted Preventive Treatment for Migraine: CGRP Monoclonal Antibodies,” the impact that CGRP monoclonal antibodies may have on migraine treatment
In the first of two presentations on the primary results of two phase III migraine prevention trials for the CGRP monoclonal antibody erenumab, also known as AMG 334, Peter Goadsby, MD, PhD, of the University of California, San Francisco, will report on the STRIVE trial in the Clinical Trials Plenary Session on April 25.
STRIVE is investigating two doses of erenumab against placebo in a 24-week trial examining the primary outcome of a change from baseline in mean monthly migraine days among 955 patients with a 1-year history of episodic migraine who are currently, have previously, or have never received migraine prophylactic medication. Patients will then be randomized after this initial double-blind treatment phase to 28 weeks of open-label active treatment with either dose of erenumab.
Later on April 25 in the Emerging Science Platform Session, David W. Dodick, MD, of the Mayo Clinic in Phoenix is set to describe the results of the phase III ARISE trial. Investigators in ARISE tested 12 weeks of one dosing regimen of erenumab versus placebo on the change from baseline in mean monthly migraine days in 577 patients with episodic migraine, followed by a 28-week open-label treatment phase.
Phase II study results of erenumab in the prevention of chronic migraine can be viewed April 28 in the “Headache: Clinical Trials and Disease Burden” platform session. The trial tested two doses of erenumab against placebo to detect differences in the change in monthly migraine days from baseline in the last 4 weeks of the trial’s 12-week double-blind treatment phase. The phase II trial results of a different CGRP monoclonal antibody known as eptinezumab or ALD403 in the prevention of chronic migraine will also be reported in the same platform session. The study evaluated a variety of doses of the drug for superiority against placebo in reducing the number of migraine days by 75% over 12 weeks.
Calcitonin gene–related peptide (CGRP) monoclonal antibodies for migraine prevention will take center stage at the upcoming annual meeting of the American Academy of Neurology in Boston in a variety of talks aimed at describing the latest clinical trial findings.
Amaal J. Starling, MD, of the Mayo Clinic, Phoenix, Ariz., will lead off on the topic in the Contemporary Clinical Issues Plenary Session on April 24 by discussing in her presentation, “The Era of Targeted Preventive Treatment for Migraine: CGRP Monoclonal Antibodies,” the impact that CGRP monoclonal antibodies may have on migraine treatment
In the first of two presentations on the primary results of two phase III migraine prevention trials for the CGRP monoclonal antibody erenumab, also known as AMG 334, Peter Goadsby, MD, PhD, of the University of California, San Francisco, will report on the STRIVE trial in the Clinical Trials Plenary Session on April 25.
STRIVE is investigating two doses of erenumab against placebo in a 24-week trial examining the primary outcome of a change from baseline in mean monthly migraine days among 955 patients with a 1-year history of episodic migraine who are currently, have previously, or have never received migraine prophylactic medication. Patients will then be randomized after this initial double-blind treatment phase to 28 weeks of open-label active treatment with either dose of erenumab.
Later on April 25 in the Emerging Science Platform Session, David W. Dodick, MD, of the Mayo Clinic in Phoenix is set to describe the results of the phase III ARISE trial. Investigators in ARISE tested 12 weeks of one dosing regimen of erenumab versus placebo on the change from baseline in mean monthly migraine days in 577 patients with episodic migraine, followed by a 28-week open-label treatment phase.
Phase II study results of erenumab in the prevention of chronic migraine can be viewed April 28 in the “Headache: Clinical Trials and Disease Burden” platform session. The trial tested two doses of erenumab against placebo to detect differences in the change in monthly migraine days from baseline in the last 4 weeks of the trial’s 12-week double-blind treatment phase. The phase II trial results of a different CGRP monoclonal antibody known as eptinezumab or ALD403 in the prevention of chronic migraine will also be reported in the same platform session. The study evaluated a variety of doses of the drug for superiority against placebo in reducing the number of migraine days by 75% over 12 weeks.
Calcitonin gene–related peptide (CGRP) monoclonal antibodies for migraine prevention will take center stage at the upcoming annual meeting of the American Academy of Neurology in Boston in a variety of talks aimed at describing the latest clinical trial findings.
Amaal J. Starling, MD, of the Mayo Clinic, Phoenix, Ariz., will lead off on the topic in the Contemporary Clinical Issues Plenary Session on April 24 by discussing in her presentation, “The Era of Targeted Preventive Treatment for Migraine: CGRP Monoclonal Antibodies,” the impact that CGRP monoclonal antibodies may have on migraine treatment
In the first of two presentations on the primary results of two phase III migraine prevention trials for the CGRP monoclonal antibody erenumab, also known as AMG 334, Peter Goadsby, MD, PhD, of the University of California, San Francisco, will report on the STRIVE trial in the Clinical Trials Plenary Session on April 25.
STRIVE is investigating two doses of erenumab against placebo in a 24-week trial examining the primary outcome of a change from baseline in mean monthly migraine days among 955 patients with a 1-year history of episodic migraine who are currently, have previously, or have never received migraine prophylactic medication. Patients will then be randomized after this initial double-blind treatment phase to 28 weeks of open-label active treatment with either dose of erenumab.
Later on April 25 in the Emerging Science Platform Session, David W. Dodick, MD, of the Mayo Clinic in Phoenix is set to describe the results of the phase III ARISE trial. Investigators in ARISE tested 12 weeks of one dosing regimen of erenumab versus placebo on the change from baseline in mean monthly migraine days in 577 patients with episodic migraine, followed by a 28-week open-label treatment phase.
Phase II study results of erenumab in the prevention of chronic migraine can be viewed April 28 in the “Headache: Clinical Trials and Disease Burden” platform session. The trial tested two doses of erenumab against placebo to detect differences in the change in monthly migraine days from baseline in the last 4 weeks of the trial’s 12-week double-blind treatment phase. The phase II trial results of a different CGRP monoclonal antibody known as eptinezumab or ALD403 in the prevention of chronic migraine will also be reported in the same platform session. The study evaluated a variety of doses of the drug for superiority against placebo in reducing the number of migraine days by 75% over 12 weeks.